Arcutis to Present at the Cantor Fitzgerald Global Healthcare Conference 2020

Rhea-AI Summary

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced its participation in the Cantor Fitzgerald Global Healthcare Conference 2020. The fireside chat presentation is scheduled for September 17, 2020, at 7:40 a.m. PT / 10:40 a.m. ET. This event focuses on the company’s developments in immune-mediated dermatological diseases. Interested parties can access the webcast through the company’s website, which will be available for replay for 30 days following the conference. Arcutis is committed to addressing unmet needs with its innovative therapies for dermatological conditions.

WESTLAKE VILLAGE, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Arcutis management will participate in a fireside chat presentation during the Cantor Fitzgerald Global Healthcare Conference 2020 taking place Sept. 15-17, 2020.

Details for the presentation are as follows:
         Cantor Fitzgerald Global Healthcare Conference 2020
         Presentation Date: Thursday, Sept. 17, 2020
         Presentation Time: 7:40 a.m. PT / 10:40 a.m. ET

The presentation will be webcast and may be accessed at the “Events & Presentations” section of the Company’s website at https://investors.arcutis.com/events-and-presentations . Arcutis will maintain an archived replay of the webcast on its website for 30 days after the conference.

About Arcutis - Bioscience, applied to the skin.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis’ robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company’s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.  For more information, visit https://www.arcutis.com or follow the company on LinkedIn and Twitter.

Investors and Media:
Heather Rowe Armstrong
Vice President, Investor Relations & Corporate Communications
harmstrong@arcutis.com
805-418-5006, Ext. 740

 

FAQ

When is the Arcutis presentation at the Cantor Fitzgerald Global Healthcare Conference 2020?

The presentation will take place on September 17, 2020, at 7:40 a.m. PT / 10:40 a.m. ET.

How can I access the Arcutis webcast for the conference?

The webcast can be accessed from the 'Events & Presentations' section of Arcutis's website.

What is the primary focus of Arcutis Biotherapeutics?

Arcutis focuses on developing treatments for unmet needs in immune-mediated dermatological diseases.

What is the stock symbol for Arcutis Biotherapeutics?

The stock symbol for Arcutis is ARQT.

Will the Arcutis presentation be available for later viewing?

Yes, the webcast will be available for replay on Arcutis's website for 30 days after the conference.